Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Last trade$170.74
Day change-$0.74 (-0.43%)
Day range$169.46 – $172.19
Volume45,365
Market cap$5.45B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.45B
Price / earnings
31.89×
Price / book
4.11×
Price / sales
4.91×
EV / sales
4.88×
EV / EBITDA
19.42×
Profitability
Earnings per share
$5.38
Return on assets
10.03%
Return on equity
12.88%
Dividend yield
0.56%
Liquidity and leverage
Debt / equity
0.02×
Current ratio
2.47×
Quick ratio
1.39×
Cash ratio
0.4×
Cash flow
Price / cash flow
24.35×
Price / free cash flow
30.61×
Free cash flow
$178M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BCPC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$290.66M
$284M
$270.71M
$263.62M
$267.56M
$255.47M
$250.52M
$240M
Cost of revenue
$184.94M
$180.31M
$169.63M
$169.72M
$172.11M
$162.35M
$162.35M
$153.67M
Gross profit
$105.71M
$103.68M
$101.08M
$93.9M
$95.45M
$93.11M
$88.17M
$86.34M
Selling, general and administrative
$37.93M
$39.93M
$39.58M
$36.56M
$36.38M
$37.37M
$32.49M
$34.38M
Research and development
$5.34M
$4.53M
$5.88M
$5.05M
$4.5M
$4.3M
$4.66M
$4.51M
Total operating expenses
$43.28M
$44.46M
$45.46M
$41.61M
$40.87M
$41.67M
$37.15M
$38.89M
Operating income
$62.44M
$59.22M
$55.63M
$52.29M
$54.58M
$51.44M
$51.02M
$47.44M
Interest expense
-$1.93M
-$1.94M
-$2.21M
$0
-$2.63M
-$2.77M
-$2.92M
$0
Income before taxes
$60.04M
$57.78M
$52.52M
$50.04M
$52.04M
$49.01M
$47.94M
$44.48M
Income taxes
$13.32M
$13.17M
$12.24M
$10.81M
$11.76M
$10.73M
$10.89M
$10.9M
Net income
$46.73M
$44.62M
$40.29M
$39.23M
$40.29M
$38.28M
$37.05M
$33.58M
Net income attributable to common shareholders
$46.73M
$44.62M
$40.29M
$39.23M
$40.29M
$38.28M
$37.05M
$33.58M
EBITDA
$74.83M
$71.44M
$68.12M
$64.01M
$66.13M
$62.85M
$62.03M
$58.34M
Basic earnings per share
$1.47
$1.40
$1.26
$1.23
$1.25
$1.18
$1.14
$1.04
Diluted earnings per share
$1.46
$1.39
$1.25
$1.21
$1.24
$1.17
$1.13
$1.02
Recent news
Company coverage with links to the original publishers.
Balchem reported record Q3 2026 sales of $291 million with 8.6% year-over-year growth. The company is expanding its science-backed specialty ingredients like VitaCholine and K2VITAL DELTA from infant nutrition into adult cognitive and cardiovascular markets. Proprietary encapsulation technology is driving adoption in animal nutrition, while a high-margin product mix is fueling segment profitability. The company achieved its 29th consecutive quarter of year-over-year adjusted EBITDA growth.
Balchem Corporation reported record third quarter 2026 results with net sales of $290.7 million (up 8.6% YoY), net earnings of $46.7 million (up 16.0% YoY), and adjusted EBITDA of $80.3 million (up 12.4% YoY). All three business segments showed healthy growth, with the company maintaining a strong balance sheet and executing strategic growth initiatives including $127 million in share repurchases over the trailing twelve months.
Balchem Corporation announced a conference call scheduled for October 23, 2026, at 11:00 AM ET to discuss third quarter 2026 financial results. CEO Ted Harris and CFO Martin Bengtsson will host the call, with results to be published prior to market opening. The call will be available via phone and webcast.
The global encapsulated lactic acid market is projected to grow from USD 1.45 billion in 2026 to USD 2.01 billion by 2031, with a CAGR of 6.72%. Growth is driven by rising demand in nutraceuticals, probiotics, and functional foods, with liquid formats showing the fastest growth at 8.02% CAGR. However, high encapsulation costs and manufacturing complexity remain key challenges. North America leads with 40.21% market share, while Asia-Pacific is the fastest-growing region at 7.62% CAGR.
The global encapsulated essential oils for feed market is projected to grow from $1.18 billion in 2026 to $1.67 billion by 2030, with a CAGR of 9.1%. Key growth drivers include rising demand for antibiotic-free livestock production, natural gut-health additives, controlled-release encapsulation technologies, and aquaculture-specific feeds, particularly in Asia-Pacific regions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Dec 23, 2025
$0.96
Jan 20, 2026
recurring
Dec 26, 2024
$0.87
Jan 17, 2025
recurring
Dec 26, 2023
$0.79
Jan 19, 2024
recurring
Dec 23, 2022
$0.71
Jan 20, 2023
recurring
Dec 27, 2021
$0.64
Jan 21, 2022
recurring
Stock splits
Historical share-structure events and their execution dates.